Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Motokazu Koga"'
Autor:
Masayuki Nakano, Motokazu Koga, Tatsuo Hashimoto, Natsuki Matsushita, Daiki Masukawa, Yusuke Mizuno, Hiraku Uchimura, Ryo Niikura, Tomoyuki Miyazaki, Fumio Nakamura, Suo Zou, Takahiro Shimizu, Motoaki Saito, Kouichi Tamura, Takahisa Goto, Yoshio Goshima
Publikováno v:
Journal of Pharmacological Sciences, Vol 148, Iss 2, Pp 214-220 (2022)
Pulmonary hypertension (PH) is a severe and progressive disease that causes elevated right ventricular systolic pressure, right ventricular hypertrophy and ultimately right heart failure. However, the underlying pathophysiologic mechanisms are poorly
Externí odkaz:
https://doaj.org/article/0731879c0abe4c7cb92a39d3bebe47cb
Publikováno v:
PLoS ONE, Vol 15, Iss 4, p e0231958 (2020)
BackgroundIt is reported that postoperative nausea and vomiting, common general anesthesia complications, may be prevented by perioperative intravenous dextrose administration, but with controversial clinical effectiveness.ObjectiveTo evaluate periop
Externí odkaz:
https://doaj.org/article/500133c3ef1e4469a7f7c0ee64353438
Publikováno v:
Journal of Pharmacological Sciences, Vol 132, Iss 1, Pp 109-112 (2016)
Through its conversion to dopamine by aromatic l-amino acid decarboxylase (AADC), l-3,4-dihydroxyphenylalanine (l-DOPA) replenishes depleted brain dopamine in Parkinson's disease patients. We recently identified GPR143 as a candidate receptor for l-D
Externí odkaz:
https://doaj.org/article/c94814368dad43e58d764c62884edacb
Publikováno v:
Journal of Pharmacological Sciences, Vol 126, Iss 1, Pp 14-20 (2014)
l-3,4-Dihydroxyphenylalanine (DOPA) is the metabolic precursor of dopamine, and the single most effective agent in the treatment of Parkinson’s disease. One problem with DOPA therapy for Parkinson’s disease is its cardiovascular side effects incl
Externí odkaz:
https://doaj.org/article/a1bd4de0e4d3440a857cc60703a3c691
Autor:
Kengo Funakoshi, Fumio Nakamura, Yoshio Goshima, Kohtaro Takizawa, Yoshie Nakamura, Yugo Fukazawa, Tatsuo Hashimoto, Daiki Masukawa, Yuka Kasahara, Koshi Murata, Motokazu Koga
Publikováno v:
Neuroscience Research. 170:370-375
Nicotine exerts its reinforcing actions by activating nicotinic acetylcholine receptors (nAChRs), but the detailed mechanisms remain unclear. Nicotine releases 3, 4-dihydroxyphenylalanine (DOPA), a neurotransmitter candidate in the central nervous sy
Autor:
Masayuki Nakano, Tatsuo Hashimoto, Motokazu Koga, Daiki Masukawa, Shinya Oku, Yusuke Mizuno, Takahisa Goto, Kouichi Tamura, Yoshio Goshima
Publikováno v:
Proceedings for Annual Meeting of The Japanese Pharmacological Society. 95:1-YIA
Autor:
Masayuki Nakano, Yoshio Goshima, Shinya Oku, Daiki Masukawa, Takahisa Goto, Motokazu Koga, Tatsuo Hashimoto, Kouichi Tamura, Yusuke Mizuno
Publikováno v:
Proceedings for Annual Meeting of The Japanese Pharmacological Society. 93:1-YIA
Autor:
Fumio Nakamura, Yoshio Goshima, Takashi Komori, Shuya Watanabe, Nobutaka Arai, Daiki Masukawa, Motokazu Koga, Erika Seki
Publikováno v:
Neuroscience research. 148
l-3,4-Dihydroxyphenylalanine (l-DOPA) has been believed to be an inert amino acid precursor of dopamine, and is the most effective therapeutic agent in Parkinson's disease (PD). We proposed l-DOPA as a neurotransmitter in the central nervous system.
Publikováno v:
Journal of Pharmacological Sciences, Vol 126, Iss 1, Pp 14-20 (2014)
l-3,4-Dihydroxyphenylalanine (DOPA) is the metabolic precursor of dopamine, and the single most effective agent in the treatment of Parkinson’s disease. One problem with DOPA therapy for Parkinson’s disease is its cardiovascular side effects incl
Autor:
Shogo Hamaguchi, Daiki Masukawa, Yoshio Goshima, Motokazu Koga, Masayuki Nakano, Tatsuo Hashimoto, Kouichi Tamura, Hikaru Tanaka
Publikováno v:
Proceedings for Annual Meeting of The Japanese Pharmacological Society. :PO2-3